

Results for announcement to the market		
AFT Pharmaceuticals Limited		
Reporting Period	12 months to 31 March 2021	
Previous Reporting Period	12 months to 31 March 2020	
Currency	NZ\$	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$113,105	Up 7%
Total Revenue	\$113,105	Up 7%
Net profit/(loss) from continuing operations	\$7,782	Down 40%
Total net profit/(loss)	\$7,782	Down 39%
Interim/Final Dividend		
Quoted Equity Securities:		
Amount per Quoted Equity Security	No dividends have been paid on ordinary shares and it is currently not proposed to pay dividends.	
Imputed amount per Quoted Equity Security	Not Applicable	
Record Date	Not Applicable	
Dividend Payment Date	Not Applicable	
Unquoted Equity Securities:		
Amount per Unquoted Redeemable Preference Share	4.7c for each payment	
Imputed Amount per Unquoted Redeemable Preference Share	4.7c for each payment	
Record Dates	20 May 2020, 30 June 2020 and 7 August 2020	
Dividend Payment Dates	20 May 2020 and 7 August 2020	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.04	(\$0.10)
A brief explanation of any of the figures above necessary to enable the figures to be understood	<p>Accompanying this announcement are the Group's audited consolidated financial statements for the twelve months ended 31 March 2021. These financial statements and the full year results commentary dated 24 May 2021 provide the balance of information requirements in accordance with NZX Listing Rule 3.5 and Appendix 2.</p> <p>Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).</p>	

	The unquoted Redeemable Preference Shares issued on 24 March 2017 attracted a dividend rate of 9.4% per annum, or 25.8 cents per share per annum. These were converted into ordinary shares by the holders during this accounting period. The dividends were paid in full in cash on or around the conversion dates and included in the above table.
Authority for this announcement	
Name of person authorised to make this announcement	Malcolm Tubby
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd
Contact phone number	+64 9 488 0232
Contact email address	malcolm@aftpharm.com
Date of release through MAP	24 May 2021

Audited financial statements accompany this announcement.